E-6201

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
E-6201
Accession Number
DB11687
Type
Small Molecule
Groups
Investigational
Description

E6201 has been investigated for the treatment of Chronic Plaque Psoriasis.

Structure
Thumb
Synonyms
Not Available
External IDs
E6201 / ER-806201
Categories
Not Available
UNII
CZP9GB25HO
CAS number
603987-35-5
Weight
Average: 389.448
Monoisotopic: 389.183837593
Chemical Formula
C21H27NO6
InChI Key
MWUFVYLAWAXDHQ-HMNLTAHHSA-N
InChI
InChI=1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1
IUPAC Name
(3S,4R,8S,9S)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,7,8,9,10-hexahydro-1H-2-benzoxacyclotetradecine-1,7-dione
SMILES
CCNC1=CC2=C(C(O)=C1)C(=O)O[C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C\C=C\2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with E-6201.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when E-6201 is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when E-6201 is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when E-6201 is combined with 5-androstenedione.Experimental, Illicit
AbciximabE-6201 may increase the anticoagulant activities of Abciximab.Approved
AcebutololE-6201 may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when E-6201 is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when E-6201 is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolE-6201 may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when E-6201 is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with E-6201.Approved
AlclofenacThe risk or severity of adverse effects can be increased when E-6201 is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when E-6201 is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Alendronic acid.Approved
AliskirenE-6201 may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Alminoprofen.Experimental
AlprenololE-6201 may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with E-6201.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when E-6201 is combined with Amcinonide.Approved
AmikacinE-6201 may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideE-6201 may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when E-6201 is combined with Aminosalicylic Acid.Approved
AmiodaroneE-6201 may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncrodE-6201 may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with E-6201.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when E-6201 is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when E-6201 is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when E-6201 is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when E-6201 is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when E-6201 is combined with Antipyrine.Approved, Investigational
Antithrombin III humanE-6201 may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when E-6201 is combined with Antrafenine.Approved
ApixabanE-6201 may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when E-6201 is combined with Apocynin.Investigational
ApramycinE-6201 may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with E-6201.Approved, Investigational
ArbekacinE-6201 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinE-6201 may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanE-6201 may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololE-6201 may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineE-6201 may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when E-6201 is combined with Atamestane.Investigational
AtenololE-6201 may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with E-6201.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with E-6201.Approved
Azficel-TThe risk or severity of adverse effects can be increased when E-6201 is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with E-6201.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with E-6201.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when E-6201 is combined with Balsalazide.Approved, Investigational
BecaplerminE-6201 may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when E-6201 is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololE-6201 may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinE-6201 may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when E-6201 is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with E-6201.Approved
BenorilateThe risk or severity of adverse effects can be increased when E-6201 is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with E-6201.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with E-6201.Approved
BenzydamineThe risk or severity of adverse effects can be increased when E-6201 is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with E-6201.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Betamethasone.Approved, Vet Approved
BetaxololE-6201 may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with E-6201.Approved, Investigational
BevantololE-6201 may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when E-6201 is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with E-6201.Approved, Investigational
BisoprololE-6201 may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinE-6201 may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololE-6201 may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when E-6201 is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when E-6201 is combined with Bucillamine.Investigational
BucindololE-6201 may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when E-6201 is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when E-6201 is combined with Bufexamac.Approved, Experimental
BufuralolE-6201 may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with E-6201.Approved
BupranololE-6201 may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with E-6201.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with E-6201.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when E-6201 is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when E-6201 is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when E-6201 is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with E-6201.Approved
CarprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololE-6201 may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolE-6201 may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with E-6201.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when E-6201 is combined with Celecoxib.Approved, Investigational
CeliprololE-6201 may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinE-6201 may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with E-6201.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with E-6201.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when E-6201 is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with E-6201.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of E-6201 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when E-6201 is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when E-6201 is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when E-6201 is combined with Cimicoxib.Investigational
CinoxacinE-6201 may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinE-6201 may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when E-6201 is combined with Cisplatin.Approved
Citric AcidE-6201 may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when E-6201 is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when E-6201 is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when E-6201 is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with E-6201.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with E-6201.Vet Approved
CloranololE-6201 may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of E-6201 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of E-6201 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when E-6201 is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when E-6201 is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when E-6201 is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with E-6201.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with E-6201.Experimental
CyclosporineE-6201 may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateE-6201 may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinE-6201 may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidE-6201 may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanE-6201 may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when E-6201 is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when E-6201 is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Delapril.Experimental
DesipramineE-6201 may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinE-6201 may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when E-6201 is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when E-6201 is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when E-6201 is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when E-6201 is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when E-6201 is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with E-6201.Approved, Investigational
DextranE-6201 may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinE-6201 may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when E-6201 is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with E-6201.Approved, Vet Approved
DicoumarolE-6201 may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when E-6201 is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when E-6201 is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when E-6201 is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with E-6201.Approved
DihydrostreptomycinE-6201 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with E-6201.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with E-6201.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with E-6201.Approved
DrospirenoneE-6201 may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when E-6201 is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when E-6201 is combined with Duvelisib.Investigational
Edetic AcidE-6201 may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanE-6201 may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when E-6201 is combined with Enalaprilat.Approved
EnoxacinE-6201 may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinE-6201 may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with E-6201.Experimental
EpanololE-6201 may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with E-6201.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with E-6201.Experimental
EplerenoneE-6201 may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with E-6201.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with E-6201.Approved
EquileninThe risk or severity of adverse effects can be increased when E-6201 is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when E-6201 is combined with Equilin.Approved
EsatenololE-6201 may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololE-6201 may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when E-6201 is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when E-6201 is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with E-6201.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when E-6201 is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when E-6201 is combined with Ethenzamide.Experimental
Ethyl biscoumacetateE-6201 may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when E-6201 is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with E-6201.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when E-6201 is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with E-6201.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with E-6201.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with E-6201.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with E-6201.Approved
FenoprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with E-6201.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when E-6201 is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Feprazone.Experimental
Ferulic acidE-6201 may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with E-6201.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when E-6201 is combined with Fish oil.Approved, Nutraceutical
FleroxacinE-6201 may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with E-6201.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Fludrocortisone.Approved, Investigational
FluindioneE-6201 may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineE-6201 may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when E-6201 is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with E-6201.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with E-6201.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when E-6201 is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when E-6201 is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with E-6201.Approved, Nutraceutical, Vet Approved
FondaparinuxE-6201 may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumE-6201 may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with E-6201.Experimental
FormestaneThe risk or severity of adverse effects can be increased when E-6201 is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Fosinopril.Approved
FramycetinE-6201 may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with E-6201.Approved, Vet Approved
GabexateE-6201 may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinE-6201 may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinE-6201 may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with E-6201.Approved, Withdrawn
GemifloxacinE-6201 may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinE-6201 may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinE-6201 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AE-6201 may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when E-6201 is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinE-6201 may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when E-6201 is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when E-6201 is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when E-6201 is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when E-6201 is combined with HE3286.Investigational
HeparinE-6201 may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when E-6201 is combined with Higenamine.Investigational
HydralazineE-6201 may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with E-6201.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with E-6201.Approved, Investigational
Hygromycin BE-6201 may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when E-6201 is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with E-6201.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with E-6201.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when E-6201 is combined with Icosapent.Approved, Nutraceutical
IdraparinuxE-6201 may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with E-6201.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when E-6201 is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with E-6201.Approved
IndenololE-6201 may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when E-6201 is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when E-6201 is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with E-6201.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with E-6201.Approved, Investigational
IsepamicinE-6201 may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with E-6201.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when E-6201 is combined with Istaroxime.Investigational
KanamycinE-6201 may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with E-6201.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with E-6201.Approved
LabetalolE-6201 may decrease the antihypertensive activities of Labetalol.Approved
LandiololE-6201 may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with E-6201.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with E-6201.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with E-6201.Approved, Investigational
LepirudinE-6201 may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanE-6201 may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololE-6201 may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololE-6201 may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinE-6201 may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with E-6201.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when E-6201 is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with E-6201.Approved
LomefloxacinE-6201 may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when E-6201 is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when E-6201 is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with E-6201.Approved
LoteprednolThe risk or severity of adverse effects can be increased when E-6201 is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with E-6201.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with E-6201.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when E-6201 is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with E-6201.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when E-6201 is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with E-6201.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when E-6201 is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Mefenamic acid.Approved
MelagatranE-6201 may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when E-6201 is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when E-6201 is combined with Meloxicam.Approved, Vet Approved
MepindololE-6201 may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when E-6201 is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with E-6201.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with E-6201.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with E-6201.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Methylprednisolone.Approved, Vet Approved
MetipranololE-6201 may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with E-6201.Approved
MetoprololE-6201 may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinE-6201 may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with E-6201.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with E-6201.Approved
MizoribineThe risk or severity of adverse effects can be increased when E-6201 is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with E-6201.Approved
MoxifloxacinE-6201 may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with E-6201.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with E-6201.Approved
NabumetoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Nabumetone.Approved
NadololE-6201 may decrease the antihypertensive activities of Nadolol.Approved
NadroparinE-6201 may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatE-6201 may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with E-6201.Approved
Nalidixic AcidE-6201 may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when E-6201 is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when E-6201 is combined with NCX 1022.Investigational
NeamineE-6201 may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololE-6201 may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinE-6201 may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinE-6201 may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when E-6201 is combined with Nepafenac.Approved, Investigational
NetilmicinE-6201 may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when E-6201 is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when E-6201 is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when E-6201 is combined with Nitroaspirin.Investigational
NorfloxacinE-6201 may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinE-6201 may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when E-6201 is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with E-6201.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with E-6201.Approved
OlsalazineE-6201 may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when E-6201 is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when E-6201 is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with E-6201.Vet Approved
OtamixabanE-6201 may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when E-6201 is combined with Oxaprozin.Approved
Oxolinic acidE-6201 may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololE-6201 may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with E-6201.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when E-6201 is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when E-6201 is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when E-6201 is combined with Parecoxib.Approved
ParomomycinE-6201 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when E-6201 is combined with Parthenolide.Approved, Investigational
PazufloxacinE-6201 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinE-6201 may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololE-6201 may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateE-6201 may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateE-6201 may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Perindopril.Approved
PhenindioneE-6201 may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonE-6201 may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with E-6201.Approved, Investigational
PindololE-6201 may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidE-6201 may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with E-6201.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with E-6201.Approved, Investigational
Piromidic acidE-6201 may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when E-6201 is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when E-6201 is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorE-6201 may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinE-6201 may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with E-6201.Approved
PomalidomideThe risk or severity of adverse effects can be increased when E-6201 is combined with Pomalidomide.Approved
Potassium CitrateE-6201 may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololE-6201 may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with E-6201.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when E-6201 is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when E-6201 is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when E-6201 is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of E-6201 can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when E-6201 is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with E-6201.Approved, Investigational
PropafenoneE-6201 may decrease the antihypertensive activities of Propafenone.Approved
PropranololE-6201 may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with E-6201.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with E-6201.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with E-6201.Vet Approved
Protein CE-6201 may increase the anticoagulant activities of Protein C.Approved
Protein S humanE-6201 may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeE-6201 may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinE-6201 may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with E-6201.Investigational
PuromycinE-6201 may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with E-6201.Approved
RamiprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when E-6201 is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when E-6201 is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinE-6201 may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinE-6201 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when E-6201 is combined with Risedronate.Approved, Investigational
RivaroxabanE-6201 may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when E-6201 is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinE-6201 may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinE-6201 may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with E-6201.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with E-6201.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when E-6201 is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with E-6201.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with E-6201.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when E-6201 is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when E-6201 is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with E-6201.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when E-6201 is combined with Serrapeptase.Investigational
SisomicinE-6201 may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinE-6201 may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateE-6201 may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of E-6201.Approved
SotalolE-6201 may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinE-6201 may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Spirapril.Approved
SpironolactoneE-6201 may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with E-6201.Investigational
StreptomycinE-6201 may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when E-6201 is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when E-6201 is combined with Sulindac.Approved, Investigational
SulodexideE-6201 may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with E-6201.Investigational
SuprofenThe risk or severity of adverse effects can be increased when E-6201 is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when E-6201 is combined with Suxibuzone.Experimental
TacrolimusE-6201 may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with E-6201.Approved
TalinololE-6201 may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with E-6201.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with E-6201.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with E-6201.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when E-6201 is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when E-6201 is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with E-6201.Approved, Investigational
TemafloxacinE-6201 may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when E-6201 is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when E-6201 is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when E-6201 is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with E-6201.Vet Approved
TerbutalineE-6201 may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with E-6201.Approved
TertatololE-6201 may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololE-6201 may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when E-6201 is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when E-6201 is combined with Tixocortol.Approved, Withdrawn
TobramycinE-6201 may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with E-6201.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when E-6201 is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with E-6201.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with E-6201.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with E-6201.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with E-6201.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when E-6201 is combined with Triamcinolone.Approved, Vet Approved
TriamtereneE-6201 may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when E-6201 is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with E-6201.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when E-6201 is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when E-6201 is combined with Trolamine salicylate.Approved
TrovafloxacinE-6201 may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinE-6201 may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when E-6201 is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with E-6201.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when E-6201 is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with E-6201.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with E-6201.Approved
WarfarinE-6201 may increase the anticoagulant activities of Warfarin.Approved
XimelagatranE-6201 may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with E-6201.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with E-6201.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when E-6201 is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when E-6201 is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with E-6201.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
10172827
PubChem Substance
347828053
ChemSpider
8348332
ChEMBL
CHEMBL1097999

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Unknown StatusTreatmentAdvanced Solid Tumors1
1, 2TerminatedTreatmentCMML / Leukemia Acute Myeloid Leukemia (AML) / Smith-Magenis Syndrome1
2CompletedTreatmentChronic Plaque Psoriasis1
2CompletedTreatmentPsoriasis Vulgaris1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.43 mg/mLALOGPS
logP3.09ALOGPS
logP2.92ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.86ChemAxon
pKa (Strongest Basic)2.98ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area116.09 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity109.72 m3·mol-1ChemAxon
Polarizability41.34 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolides and analogues
Sub Class
Not Available
Direct Parent
Macrolides and analogues
Alternative Parents
Secondary alkylarylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Secondary alcohols / Lactones / Cyclic ketones / Carboxylic acid esters / Amino acids and derivatives / 1,2-diols
show 3 more
Substituents
Macrolide / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Secondary aliphatic/aromatic amine / Benzenoid / Vinylogous acid / 1,2-diol / Amino acid or derivatives / Carboxylic acid ester
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:40 / Updated on June 02, 2018 08:29